DrugPatentWatch Database Preview
Details for Patent: 9,034,867
Which drugs does patent 9,034,867 protect, and when does it expire?
This patent has twenty-four patent family members in twenty-two countries.
Summary for Patent: 9,034,867
Title: | Pharmaceutical compositions comprising sorbitan esters |
Abstract: | The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs. |
Inventor(s): | Perry; Jason M. (Cambridge, MA), Deaver; Daniel R. (Franklin, MA), Hickey; Magall B. (Medford, MA), Remenar; Julius F. (Waltham, MA), Vandiver; Jennifer (Arlington, MA) |
Assignee: | ALKERMES PHARMA IRELAND LIMITED (Dublin, IE) |
Application Number: | 13/423,606 |
Patent Claim Types: see list of patent claims | Composition; Compound; Delivery; Use; |
Drugs Protected by US Patent 9,034,867
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-001 | Oct 5, 2015 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | TREATMENT OF SCHIZOPHRENIA | ➤ Try a Free Trial | |||
Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-002 | Oct 5, 2015 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | TREATMENT OF SCHIZOPHRENIA | ➤ Try a Free Trial | |||
Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-003 | Oct 5, 2015 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | TREATMENT OF SCHIZOPHRENIA | ➤ Try a Free Trial | |||
Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-004 | Jun 5, 2017 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | TREATMENT OF SCHIZOPHRENIA | ➤ Try a Free Trial | |||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 9,034,867
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
9,351,976 | Pharmaceutical compositions comprising sorbitan esters | ➤ Try a Free Trial |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 9,034,867
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2012231160 | ➤ Try a Free Trial | |||
Australia | 2017204486 | ➤ Try a Free Trial | |||
Brazil | 112013023847 | ➤ Try a Free Trial | |||
Canada | 2830511 | ➤ Try a Free Trial | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |